P.F. Bruning
Radiation Effects Research Foundation · 72 works · 2,834 citations · h-index 22
Top works
- Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over
- Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
- MAM-6 antigen, a new serum marker for breast cancer monitoring.
- Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study
- Body fat mass, body fat distribution, and pubertal development: a longitudinal study of physical and hormonal sexual maturation of girls
- Relation of Serum Levels of Testosterone and Dehydroepiandrosterone Sulfate to Risk of Breast Cancer in Postmenopausal Women
- Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer
- Body measurements, estrogen availability and the risk of human breast cancer: A case‐control study
- The quality of life of long-term survivors of Hodgkin's disease
- Body Fat Mass, Body Fat Distribution, and Plasma Hormones in Early Puberty in Females
- Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk
- Endogenous estrogens and breast cancer a possible relationship between body fat distribution and estrogen availability
- Response of leptomeningeal metastases from breast cancer to hormonal therapy
- EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer
- Prothrombal: A New Concentrate of Human Prothrombin Complex for Clinical Use
- Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist
- A Sandwich-Radioimmunoassay for a New Antigen (Mam-6) Present in the Sera of Patients with Metastasized Carcinomas
- A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923
- Factors influencing waist/hip ratio in randomly selected pre- and post-menopausal women in the dom-project (preliminary results).
- AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)